报价延迟最少15分钟:2026/07/17 15:48 EDT
盘后时段
|
||||
|
-- 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
106.81
|
|
|
| 价值评估 |
|
盈利(现时/预测)
4.19/7.01
|
|
企业价值
7.46B
|
| 资产负债 |
|
每股账面净值
18.62
|
| 现金流量 |
|
现金流量率
0.06
|
| 损益表 |
|
收益
1.54B
|
|
每股收益
18.52
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, PrecisionDiagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements inEurope, Canada, Australia, Asia-Pacific, Central America and South America. |
